How to manage lower-risk myelodysplastic syndromes
Author:
- 9 September 2011
- journal article
- Published by Springer Nature in Leukemia
- Vol. 26 (3) , 390-394
Abstract
Patients with lower-risk myelodysplastic syndromes (MDSs), usually defined as having an International Prognostic Scoring System score of 1.0 or less, and/or <5% myeloblasts, comprise the majority of newly diagnosed and established MDS patients and have a survival measured in years. Most will eventually require therapy for their disease, usually when MDS-related symptoms or transfusion requirements accelerate and outweigh potential drug-related toxicities. The decision of when to initiate therapy is far from straightforward. Erythropoiesis stimulating agents yield responses in up to 40% of appropriately selected patients, while disease-modifying drugs, including lenalidomide, azacitidine, decitabine and anti-thymocyte globulin, can evoke responses as high as 67% in patient subgroups. Newer therapies hold the promise of activity in patients who have failed standard regimens.Keywords
This publication has 51 references indexed in Scilit:
- Prognostic impact of SNP array karyotyping in myelodysplastic syndromes and related myeloid malignanciesBlood, 2011
- Alemtuzumab Treatment of Intermediate-1 Myelodysplasia Patients Is Associated With Sustained Improvement in Blood Counts and Cytogenetic RemissionsJournal of Clinical Oncology, 2010
- Subcutaneous or intravenous administration of romiplostim in thrombocytopenic patients with lower risk myelodysplastic syndromesCancer, 2010
- A critical role for phosphatase haplodeficiency in the selective suppression of deletion 5q MDS by lenalidomideProceedings of the National Academy of Sciences, 2009
- Aberrant DNA methylation is a dominant mechanism in MDS progression to AMLBlood, 2009
- Relationship of Treatment-Related Cytopenias and Response to Lenalidomide in Patients With Lower-Risk Myelodysplastic SyndromesJournal of Clinical Oncology, 2008
- Characteristics of US Patients with Myelodysplastic Syndromes: Results of Six Cross-sectional Physician SurveysJNCI: Journal of the National Cancer Institute, 2008
- Identification of RPS14 as a 5q- syndrome gene by RNA interference screenNature, 2008
- A Decision analysis to determine the appropriate treatment for low‐risk myelodysplastic syndromesCancer, 2007
- Health, economic, and quality-of-life effects of erythropoietin and granulocyte colony-stimulating factor for the treatment of myelodysplastic syndromes: a randomized, controlled trialBlood, 2004